ADC Therapeutics SA (ADCT) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 9, 2022 7:00 AM EDTZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.3 million in the second quarter of 2022
Ex-U.S. ZYNLONTA license agreement with Sobi® facilitates global patient access and extends cash runway into early 2025
Company to host conference call today at 8:30 a.m. EDT
LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
The ZYNLONTA® launch is advancing steadily as we continue to increase... More
